Abstract：Objective To investigate the application of endoscopic retrograde cholangiopancreatography (ERCP) in children and the risk factors for post-ERCP pancreatitis (PEP). Methods A retrospective analysis was conducted on the clinical data of 66 children, aged ≤16 years, who underwent ERCP for pancreaticobiliary diseases at the Gastrointestinal Endoscopy Center of the Second Affiliated Hospital of Kunming Medical University from September 2013 to September 2023. The incidence rate of PEP and the risk factors for the development of PEP were analyzed. Results A total of 78 ERCP procedures were performed on 66 children, with 5 diagnostic ERCPs, 69 therapeutic ERCPs, and 4 failed procedures. The success rate of ERCP operations was 95% (74/78). There were 17 cases of PEP in total, with an incidence rate of 22%. In the PEP group, the proportion of children with normal preoperative bilirubin and the proportion of guidewire insertion into the pancreatic duct during surgery were higher than in the non-PEP group (P<0.05). The multivariate logistic regression analysis showed that guidewire insertion into the pancreatic duct was an independent risk factor for PEP (P<0.05). Conclusions With the increasing application of ERCP in children with pancreaticobiliary diseases, it is important to select an appropriate intubation technique during surgery to avoid blindly entering the guidewire into the pancreatic duct and reduce the occurrence of PEP.
YANG Lu,FU Yan,SUN Zheng-Hao et al. Risk factors for pancreatitis after endoscopic retrograde cholangiopancreatography in children[J]. CJCP, 2024, 26(7): 690-694.
Perera KDR, Nawarathne NMM, Samarawickrama VT, et al. Endoscopic retrograde cholangiopancreatography in children: feasibility, success, and safety with standard adult endoscopes and accessories[J]. Pediatr Gastroenterol Hepatol Nutr, 2022, 25(5): 406-412. PMID: 36148288. PMCID: PMC9482827. DOI: 10.5223/pghn.2022.25.5.406.
Asenov Y, Ak?n M, Cantez S, et al. Endoscopic retrograde cholangiopancreatography in children: retrospective series with a long-term follow-up and literature review[J]. Turk J Gastroenterol, 2019, 30(2): 192-197. PMID: 30459128. PMCID: PMC6408168. DOI: 10.5152/tjg.2018.18165.
Mercier C, Pioche M, Albuisson E, et al. Safety of endoscopic retrograde cholangiopancreatography in the pediatric population: a multicenter study[J]. Endoscopy, 2021, 53(6): 586-594. PMID: 32599632. DOI: 10.1055/a-1209-0155.
Prasil P, Laberge JM, Barkun A, et al. Endoscopic retrograde cholangiopancreatography in children: a surgeon's perspective[J]. J Pediatr Surg, 2001, 36(5): 733-735. PMID: 11329577. DOI: 10.1053/jpsu.2001.22948.
Tryliskyy Y, Bryce GJ. Post-ERCP pancreatitis: pathophysiology, early identification and risk stratification[J]. Adv Clin Exp Med, 2018, 27(1): 149-154. PMID: 29521055. DOI: 10.17219/acem/66773.
Troendle DM, Abraham O, Huang R, et al. Factors associated with post-ERCP pancreatitis and the effect of pancreatic duct stenting in a pediatric population[J]. Gastrointest Endosc, 2015, 81(6): 1408-1416. PMID: 25686874. DOI: 10.1016/j.gie.2014.11.022.
Dumonceau JM, Andriulli A, Elmunzer BJ, et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline—updated June 2014[J]. Endoscopy, 2014, 46(9): 799-815. PMID: 25148137. DOI: 10.1055/s-0034-1377875.
Martínez-Moneo E, Cárdenas-Jaén K, Fernández-Laso AB, et al. Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Pancreatology, 2020, 20(5): 801-805. PMID: 32448748. DOI: 10.1016/j.pan.2020.05.002.
Palomera-Tejeda E, Shah MP, Attar BM, et al. Pharmacological and endoscopic interventions for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Gastroenterology Res, 2023, 16(3): 149-156. PMID: 37351082. PMCID: PMC10284647. DOI: 10.14740/gr1620.
